期刊文献+

米力农治疗急性心力衰竭的效果及对NT-proBNP的影响分析 被引量:4

下载PDF
导出
摘要 目的:对米力农在急性心力衰竭疾病治疗中的临床应用效果进行观察,且分析其对NT-proBNP(B型纳尿肽前体)的影响。方法:选取我院2014年1月至2015年1月所接收的64例急性心力衰竭患者作为研究的对象,按随机数字表法分成观察组与对照组,对照组予以常规治疗,在此基础之上,对观察组予以米力农治疗,且对两组患者的治疗效果、NT-proBNP等加以观察与比较。结果:观察组患者的治疗有效率(71.86%)高于对照组(56.25%),差异显著,有统计学意义(P<0.05);观察组治疗后7d的NT-proBNP指标低于对照组,存在显著性的差异,有统计学意义(P<0.05);观察组患者的心血管发生率、死亡率以及再次住院率等均低于对照组,存在显著性的差异,有统计学意义(P<0.05)。结论:在常规治疗基础之上,对急性心力衰竭患者予以米力农治疗,疗效确切,且能对NT-proBNP水平进行有效的控制,值得在临床上大力推行。
作者 谢常平
出处 《黑龙江医药》 CAS 2016年第4期671-673,共3页 Heilongjiang Medicine journal
  • 相关文献

参考文献6

二级参考文献38

  • 1Nieminen MS, Bohm M, Cowie MR, et al. Executive sum mary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acute heart failure of the euro- pean society of cardiology[J]. Eur Heart J, 2005,26: 384- 416.
  • 2Kopustinskiene DM, Pollesello P, Saris NE. Levosimendan is a mitochondrial KATP channel opener[J]. Eur J Pharma col, 2001,428:311-314.
  • 3Kersten JR, Montgomery MW, Pagel PS, et al. Levosimen- dan a new positive inotropic drug, decreases myocardial in- farct size via activation of KATP channels[J]. Anesth Analg, 2000,90 : 5-11.
  • 4Toller WG, Stranz C. Levosimendan, a new inotropic andvasodilator agent [J]. Anesthesiology, 2006, 104 (3) : 556- 569.
  • 5Avgeropoulou C, Andreadou I, Markantonis Kyroudis S, et al. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-infiammatory cytokine levels in pa- tients with advanced decompensated heart failure in compari- son to dobutamine[J]. Eur J Heart Fail,2005,7 : 882-887.
  • 6Lee SC, Stevens TL, Sandberg SM,et al. The potential of brain natriuretic peptide as biomarker for New York Heart Association class during the outpatient treatment of heart failure[J]. J Card Fail, 2002,8 : 149-154.
  • 7Lemos J, McGuire D, Drazller M, et al. B type natriuretic piptide in cardiovascular disease[J]. Lancet, 2003,362 : 316- 322.
  • 8Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in se- vere low-output heart failure(the LIDO study) :a randomized double-blind trilal[J]. Lancet, 2002,360 : 196-202.
  • 9Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failture: the SURVIVE randomized trial[J]. JAMA, 2007, 279:1883- 1891.
  • 10Moiseyev VS, Poder P, Andrejevs N, et al. Safety and effica- cy of a novel calcium sensitizer, levosimendan in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double blind study (RUS- SLAN) [J]. Eur Heart J, 2002,23 : 1422-1432.

共引文献61

同被引文献24

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部